最新发布
新朝阳与华南农大签署战略合作协议,共推植物源农药协同创新与全球化
大农化网报道:2026年8月12日,成都新朝阳作物科学股份有限公司(以下简称″新朝阳″)与华南农业大学在成都天府国际生物城新朝阳总部举行战略合作签约仪式。新朝阳董事长何其明与华南农业大学徐汉虹教授分别代表双方签署战略合作框架协议,携手推进植…
Dyadic Expands Animal-Free Dairy Protein Pipeline with European Partnership
Dyadic International is adding more cow-free dairy proteins to its pipeline via a new development and commercial license partnership with a European biotech company.
广西大学在纳米制剂提高水稻对南方黑条矮缩病抗性方面取得新进展
南方水稻黑条矮缩病是近十年来影响我国及周边国家水稻生产的主要病毒病害之一,严重威胁我国的粮食安全,该病害的病原南方水稻黑条矮缩病毒 (Southern rice black-streaked dwarf virus, SRBSDV) 是隶属…
警惕!江南及长江中下游局部稻区稻飞虱偏重至大发生态势明显
大农化网报道:据全国农技推广中心,截至8月9日,稻飞虱全国发生面积1.16亿亩次,与近5年同期基本持平,比近10年同期低10%。受华南东部、江南中西部、长江中下游等地持续降雨及台风″白海豚″外围环流影响,稻飞虱异地迁入与田间增殖叠加,江南及…
硫虫酰胺首批混剂登记落地!20余项复配专利储备进入转化收获期
大农化网报道:近日,浙江宇龙药业有限公司成功取得硫虫酰胺分别与甲氨基阿维菌素(14.6% SC)、虫螨腈(25% SC)和高效氯氟氰菊酯(12.5% SC)的复配产品,均用于防治甘蓝小菜蛾。 这是硫虫酰胺这一国产创制化合物实现商业化以来,首…
逃离″重力陷阱″,生物制剂行业如何建立独立的运行框架?
大农化网报道: 农业生物制剂行业从未获得过如此多的企业支持、战略关注或监管重心。但是为什么农民在近四年里对其的信任度几乎毫无增长?本文的观点是,障碍并非来自沟通,而是来自架构 —— 摆脱这一困境意味着要建立一个专为活体技术设计、而不是从化学…
利润压缩叠加信贷收紧,巴西大豆种植面积预计首迎″平台期″
大农化网报道:经历了二十余年的快速持续扩张后,巴西大豆种植面积的增长预计将在2026/27年度按下暂停键。这一转折对于全球油籽市场及农资需求而言,标志着一次重要的变化节点。 据荷兰合作银行旗下研究机构RaboResearch发…
Bakuchiol ferulate matches retinol efficacy with less skin irritation, study finds
Cosmetic research from Shenzhen HBN Technology spotlights bakuchiol ferulate — a novel molecular hybrid synthesized from bakuchiol and a ferulic acid — as a stable, well-tolerated, and effective alternative to anti-aging retinol. Authors of the study highlight that retinol’s clinical utility as a potent wrinkle-reducing active ingredient is often limited by its chemical instability and irritation for sensitive skin.
L’Oréal and NUS partner to test skin’s role in whole-body aging
L’Oréal and the National University of Singapore (NUS) Medicine have launched a multi-year strategic research partnership to investigate the skin’s role in overall longevity. The collaboration aims to close a gap in skin aging science by exploring its role in how the rest of the body ages over time, potentially leading to more preventive approaches.
Financial Value of AI Agents in Drug Development
A new Tufts Center for the Study of Drug Development (CSDD) analysis shows that an AI clinical monitoring agent can deliver net financial gains as high as $21 million per drug development program and 82 times the return on investment.
